Indications And Dose
Small cell carcinoma of the bronchus, the lymphomas and testicular cancer ▶BY MOUTH ▶Adult: 120–240 mg/m2 daily for 5 days ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)
Source page 996
Loading InternPractice…
Individual generic drug information
Extracted information for Etoposide only.
Small cell carcinoma of the bronchus, the lymphomas and testicular cancer ▶BY MOUTH ▶Adult: 120–240 mg/m2 daily for 5 days ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)
Source page 996
Extracted information for Etoposide only.
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.
Source page 996
→Appendix 1: etoposide
Source page 996
GENERAL SIDE-EFFECTS ▶Common or very common Abdominal pain. acute leukaemia. alopecia. anaemia. appetite decreased. arrhythmia. asthenia. bone marrow depression. constipation. diarrhoea. dizziness. hepatotoxicity. hypertension. leucopenia. malaise. mucositis. myocardial infarction. nausea. neutropenia. skin reactions. thrombocytopenia. vomiting ▶Uncommon Nerve disorders ▶Rare or very rare Dysphagia. neurotoxicity. radiation recall reaction. respiratory disorders. seizure. severe cutaneous adverse reactions (SCARs). taste altered. vision loss SPECIFIC SIDE-EFFECTS ▶Common or very common ▶With intravenous use Anaphylactic reaction. hypotension. infection ▶With oral use Oesophagitis. stomatitis. transient systolic hypotension ▶Uncommon ▶With intravenous use Haemorrhage ▶Rare or very rare ▶With intravenous use Fever ▶With oral use Drowsiness ▶Frequency not known ▶With intravenous use Angioedema. extravasation necrosis. infertility. tumour lysis syndrome
Source page 996
Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 938.
Source page 996
Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
Source page 996
Discontinue breast-feeding.
Source page 996
Manufacturer advises caution (increased risk of accumulation).
Source page 996
Dose adjustments Consider dose reduction—consult local treatment protocol for details.
Source page 996
Extracted information for Etoposide only.
Etoposide may be given orally or by slow intravenous infusion, the oral dose being double the intravenous dose. A preparation containing etoposide phosphate can be given by intravenous injection or infusion. Etoposide is usually given daily for 3–5 days and courses should not be repeated more frequently than at intervals of 21 days.
Source page 996
There can be variation in the licensing of different medicines containing the same drug. Solution for infusion ▶Etoposide (Non-proprietary) Etoposide 20 mg per 1 ml Etoposide 100mg/5ml concentrate for solution for infusion vials | 1 vial P £11.50–£16.29 (Hospital only) Etoposide 200mg/10ml concentrate for solution for infusion vials | 1 vial P s (Hospital only) Etoposide 500mg/25ml concentrate for solution for infusion vials | 1 vial P £60.70–£81.42 (Hospital only) Capsule CAUTIONARY AND ADVISORY LABELS 23 ▶Vepesid (Cheplapharm Arzneimittel GmbH) Etoposide 50 mg Vepesid 50mg capsules | 20 capsule P £99.82 Etoposide 100 mg Vepesid 100mg capsules | 10 capsule P £87.23 Powder for solution for injection ▶Etopophos (Cheplapharm Arzneimittel GmbH) Etoposide (as Etoposide phosphate) 100 mg Etopophos 100mg powder for solution for injection vials | 10 vial P £261.68 ANTINEOPLASTIC DRUGS › TAXANES
Source page 996
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
120–240 mg/m2 daily for 5 days
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 996
First line only; read the complete Indications and dose section above.
(consult product literature)
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 996